The enhancing effects of heparin on the biological activity of FGF-2 in heparin−FGF-2−calcium phosphate composite layers
Source abstract
Abstract
Orthopedic and dental implants coated with fibroblast growth factor-2 (FGF-2)-calcium phosphate composite layers promote dermis formation, bone formation, and angiogenesis because of the biological activity of FGF-2. Enhancing the biological activity of FGF-2 in the composite layers is important for its wider application in orthopedics and dentistry. This study incorporated low-molecular-weight heparin (LMWH) into the FGF-2-calcium phosphate composite layers and clarified the enhancing effects of LMWH on the biological activity of FGF-2 in the composite layers in vitro. LMWH-FGF-2-calcium phosphate composite layers were successfully formed on zirconia in supersaturated calcium phosphate solutions. The composite layers comprised continuous and macroscopically homogeneous layers and particles smaller than 500 nm in size composed of amorphous calcium phosphate. The amounts of Ca and P deposited on zirconia remained almost unchanged with the addition of LMWH under the presence of FGF-2 in the supersaturated calcium phosphate solution. The LMWH in the supersaturated calcium phosphate solution increased the stability of FGF-2 in the solution and the amount of FGF-2 in the composite layers. The LMWH in the composite layers increased the mitogenic and endothelial tube-forming activities of FGF-2, and FGF-2 activity of inducing osteogenic differentiation gene expression pattern in the composite layers. Our results indicate that the enhanced biological activity of FGF-2 in the LMWH-FGF-2-calcium phosphate composite layers is attributed to an LMWH-mediated increase in the amount of FGF-2, which maintains its biological activity in the supersaturated calcium phosphate solution and the composite layers. The LMWH-FGF-2-calcium phosphate composite layer is a promising coating for orthopedic and dental implants. STATEMENT OF SIGNIFICANCE: Orthopedic and dental implants coated with fibroblast growth factor-2 (FGF-2)-calcium phosphate composite layers promote dermis formation, bone formation, and angiogenesis because of the biological activity of FGF-2. Enhancing the biological activity of FGF-2 in the layers is important for wider its application in orthopedics and dentistry. This study demonstrates the enhancing effects of low-molecular-weight heparin (LMWH) contained within LMWH-FGF-2-calcium phosphate composite layers on the biological activity of FGF-2 in vitro. Our results indicate that the enhanced biological activity of FGF-2 within the composite layers arises from an LMWH-mediated increase in the amount of FGF-2, which maintains its biological activity in the LMWH-FGF-2-calcium phosphate composite layers and supersaturated calcium phosphate solutions used for coating the composite layers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Endodontics and Root Canal Treatments · Proteoglycans and glycosaminoglycans research · Bone health and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (74)
Show source-provided references
1. Reducing the risk of impaired bone apposition to titanium screws with the use of fibroblast growth factor-2-apatite composite layer coating10.1186/s13018-016-0501-z ↗
2. Enhanced bone formation using hydroxyapatite ceramic coated with fibroblast growth factor-210.1016/j.actbio.2009.12.045 ↗
3. Formation of a FGF-2 and calcium phosphate composite layer on a hydroxyapatite ceramic for promoting bone formation10.1088/1748-6041/2/3/S16 ↗
4. Angiogenesis therapy for brain infarction using a slow-releasing drug delivery system for fibroblast growth factor 210.1016/j.bbrc.2013.01.013 ↗
5. Fibroblast growth factor-210.1016/S1357-2725(99)00133-8 ↗
6. Fibroblast growth factor-210.1016/S1357-2725(99)00123-5 ↗
7. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells10.1371/journal.pone.0059083 ↗
8. High-frequency repetitive transcranial magnetic stimulation mitigates depression-like behaviors in CUMS-induced rats via FGF2/FGFR1/p-ERK signaling pathway10.1016/j.brainresbull.2022.02.020 ↗
9. Impacts of chemically different surfaces of implants on a biological activity of fibroblast growth factor-2-apatite composite layers formed on the implants10.1016/j.otsr.2020.102748 ↗
10. Initial clinical trial of pins coated with fibroblast growth factor-2-apatite composite layer in external fixation of distal radius fractures10.1016/j.jor.2018.12.012 ↗
11. The calcium phosphate matrix of FGF-2-apatite composite layers contributes to their biological effects10.3390/ijms150610252 ↗
12. Fibroblast growth factor-2-apatite composite layers on titanium screw to reduce pin tract infection rate10.1002/jbm.b.31029 ↗
13. Enhanced wound healing associated with Sharpey's fiber-like tissue formation around FGF-2-apatite composite layers on percutaneous titanium screws in rabbits10.1007/s00402-011-1381-7 ↗
14. Ascorbate-apatite composite and ascorbate-FGF-2-apatite composite layers formed on external fixation rods and their effects on cell activity in vitro10.1016/j.actbio.2009.03.020 ↗
15. Stoichiometry of heparin binding to basic fibroblast growth factor10.1006/abbi.1994.1037 ↗
16. Heparin stabilizes FGF-2 and modulates striatal precursor cell behavior in response to EGF10.1016/j.expneurol.2004.05.007 ↗
17. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation10.1083/jcb.107.2.743 ↗
18. Heparin protects basic and acidic FGF from inactivation10.1002/jcp.1041280317 ↗
19. Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier10.2147/IJN.S8692 ↗
20. Structure-guided design, generation, and biofunction of PEGylated fibroblast growth factor 2 variants for wound healing10.1039/D0NR05999D ↗
21. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization10.1016/S1097-2765(00)00073-3 ↗
22. Fibroblast Growth Factor 2 Protein Stability Provides Decreased Dependence on Heparin for Induction of FGFR Signaling and Alters ERK Signaling Dynamics10.3389/fcell.2019.00331 ↗
23. Heparan sulfate domains required for fibroblast growth factor 1 and 2 signaling through fibroblast growth factor receptor 1c10.1074/jbc.M116.761585 ↗
24. A heparin-mimicking block copolymer both stabilizes and increases the activity of fibroblast growth factor 2 (FGF2)10.1021/acs.biomac.6b01182 ↗
25. Poly(vinyl sulfonate) facilitates bFGF-induced cell proliferation10.1021/acs.biomac.5b00557 ↗
26. A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor10.1038/nchem.1573 ↗
27. Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium10.1073/pnas.0806136105 ↗
28. Effect of controlled release of fibroblast growth factor-2 from chitosan/fucoidan micro complex-hydrogel on in vitro and in vivo vascularization10.1002/jbm.a.31563 ↗
29. Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells10.1002/stem.1021 ↗
30. Protective effect of FGF-2 and low-molecular-weight heparin/protamine nanoparticles on radiation-induced healing-impaired wound repair in rats10.1093/jrr/rrx044 ↗
31. In situ hydrogel dressing loaded with heparin and basic fibroblast growth factor for accelerating wound healing in rat10.1016/j.msec.2020.111169 ↗
32. Zirconia versus titanium in dentistry: a review10.4012/dmj.2019-172 ↗
33. Influence of sterilization on the performance of anodized nanoporous titanium implants10.1016/j.msec.2021.112429 ↗
34. Zirconia surface modifications for implant dentistry10.1016/j.msec.2019.01.062 ↗
35. First clinical study of a novel complete metal-free ceramic total knee replacement system10.1186/s13018-016-0352-7 ↗
36. Biological activity of terminally gamma-ray-sterilized titanium and hydroxyapatite coated with a growth factor−apatite composite layer
37. Development of novel zirconia implant's materials gradated design with improved bioactive surface10.1016/j.jmbbm.2019.02.022 ↗
38. Modification of the Ceramic Implant Surfaces from Zirconia by the Magnetron Sputtering of Different Calcium Phosphate Targets: a Comparative Study10.3390/ma11101949 ↗
39. Cell attachment and proliferation of bone marrow-derived osteoblast on zirconia of various surface treatment10.4047/jap.2014.6.2.96 ↗
40. Crystalline hydroxyapatite coating by hydrolysis using β-tricalcium phosphate target by pulsed-laser deposition10.35848/1347-4065/abfc31 ↗
41. Stable sol-gel hydroxyapatite coating on zirconia dental implant for improved osseointegration10.1007/s10856-021-06550-6 ↗
42. Biomimetic in situ precipitation of calcium phosphate containing silver nanoparticles on zirconia ceramic materials for surface functionalization in terms of antimicrobial and osteoconductive properties10.1016/j.dental.2020.09.018 ↗
43. Role of magnesium and the effect of surface roughness on the hydroxyapatite-forming ability of zirconia induced by biomimetic aqueous solution treatment10.3390/ma13143045 ↗
44. Bone tissue responses to zirconia implants modified by biomimetic coating incorporated with BMP-210.11607/prd.3980 ↗
45. Surface characterization of commercially available yttria-stabilized tetragonal zirconia polycrystalline in water and Hanks' solution using X-ray photoelectron spectroscopy10.4012/dmj.2018-299 ↗
46. Biomimetic coating of laminin-apatite composite on titanium metal and its excellent cell-adhesive properties10.1002/adma.200400152 ↗
47. Proteins incorporated into biomimetically prepared calcium phosphate coatings modulate their mechanical strength and dissolution rate10.1016/S0142-9612(02)00252-1 ↗
48. Enhanced biocompatibility and improved osteogenesis of coralline hydroxyapatite modified by bone morphogenetic protein 2 incorporated into a biomimetic coating10.1016/j.msec.2018.11.017 ↗
49. Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy10.1016/j.actbio.2013.03.031 ↗
50. Surface-mediated gene transfer from nanocomposites of controlled texture10.1038/nmat1179 ↗
51. Novel gene-transferring scaffolds having a cell adhesion molecule-DNA-apatite nanocomposite surface10.1038/sj.gt.3303041 ↗
52. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes10.1016/j.jconrel.2010.06.024 ↗
53. Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: effect on growth retardation of established colon tumor10.1371/journal.pone.0060428 ↗
54. Biomimetic apatite formed on cobalt-chromium alloy: a polymer-free carrier for drug eluting stent10.1016/j.colsurfb.2016.12.021 ↗
55. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma10.1186/1748-717X-8-239 ↗
56. The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis10.1042/BSR20170173 ↗
57. Effect of an oversulfated exopolysaccharide on angiogenesis induced by fibroblast growth factor-2 or vascular endothelial growth factor in vitro10.1016/j.bcp.2004.11.021 ↗
58. Nucleosomes bind fibroblast growth factor-2 for increased angiogenesis in vitro and in vivo10.1158/1541-7786.281.2.5 ↗
59. Heparin impairs angiogenesis through inhibition of microRNA-10b10.1074/jbc.M111.224212 ↗
60. Bone morphogenetic protein is required for fibroblast growth factor 2-dependent later-stage osteoblastic differentiation in cranial suture cells
61. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx210.1074/jbc.M203750200 ↗
62. FGF-2 promotes osteocyte differentiation through increased E11/podoplanin expression10.1002/jcp.26345 ↗
63. Bone Morphogenetic Protein-2 in Development and Bone Homeostasis10.3390/jdb8030019 ↗
64. Role and regulation of RUNX2 in osteogenesis10.22203/eCM.v028a19 ↗
65. Type-I collagen produced by distinct fibroblast lineages reveals specific function during embryogenesis and Osteogenesis Imperfecta10.1038/s41467-021-27563-3 ↗
66. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: a randomized, placebo-controlled trial10.1002/jbmr.146 ↗
67. Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy10.1002/jor.20315 ↗
68. Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-210.1210/jcem.86.2.7199 ↗
69. Skin Wound Healing: an Update on the Current Knowledge and Concepts10.1159/000454919 ↗
70. Wound Healing Problems in the Mouth10.3389/fphys.2016.00507 ↗
71. Gatifloxacine-loaded PLGA and beta-tricalcium phosphate composite for treating osteomyelitis10.4012/dmj.2010-098 ↗
72. Half-life modeling of basic fibroblast growth factor released from growth factor-eluting polyelectrolyte multilayers10.1038/s41598-021-89229-w ↗
73. Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease10.1177/00912700122010230 ↗
74. Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling: evidence in support of the "cooperative end structures" model10.1074/jbc.M106608200 ↗